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Sphingolipids in general and ceramides in particular, contribute to pathophysiological mechanisms by 
modifying signalling and metabolic pathways. Here, we present the available evidence for a 
bidirectional homeostatic crosstalk between sphingolipids and glycerophospholipids, whose 
dysregulation  contribute to lipotoxicity induced metabolic stress. The initial evidence for this crosstalk 
originates from simulated models designed to investigate the biophysical properties of sphingolipids in 
plasma membrane representations. In this review, we reinterpret some of the original findings and 
conceptualise them as a sort of “ying/yang” interaction model of opposed/complementary forces, which 
is consistent with the current knowledge of lipid homeostasis and pathophysiology. We also propose 
that the dysregulation of the balance between sphingolipids and glycerophospholipids results in a 
lipotoxic insult relevant in the pathophysiology of common metabolic diseases, typically characterised 









cytidylyltransferase  A,  [CERK]  Ceramide  Kinase,  [C1P]  Ceramide‐1‐phosphate,  [CerS]  Ceramide 
Synthase,  [CERT]  ceramide  transport  protein,  [HDL]  High‐density  lipoproteins,  [PAF]  Platelet 
activating factor, [PC] phosphatidylcholine, [PE] Phosphatidylethanolamine, [PH] Pleckstrin homology 
domain,  [PI]  Phosphatidylinositol,  [PI3K]  Phosphatidylinositol  3‐kinase,  [PLA2]  Phospholipase  A2, 










In the context of common metabolic diseases such as obesity, diabetes or non-alcoholic fatty 
liver disease (NAFLD), the concept of “lipotoxicity” refers to the inappropriate ectopic accumulation 
of lipids in non-adipose organs causing metabolic stress and dysfunction. Lipotoxicity in liver, skeletal 
muscle, heart, pancreas or brain has been identified as an important pathogenic contributor to their 
metabolic dysfunction. Lipotoxicity can operate at multiple levels spanning from cellular to organ levels 
and involves a repertoire of characteristic biochemical mediators. The severity of the lipotoxic insult is 
modulated by the specific cellular genetic vulnerability to the toxicity induced by lipids. When at 
physiological concentrations, most of these lipid species exert important physiological functions that 
contribute to structural, signalling or cellular homeostasis. Hence, these lipids per se only become toxic 
when: a) they accumulate in excessive quantities as a result of exacerbated biosynthesis and/or impaired 
turnover; b) they exhibit distorted qualitative properties (e.g. both biologically or chemically induced) 
and/or c) when their spatio-temporal location in the cell is atypical (being in the wrong place at the 
wrong time).  
When in excess, sphingolipids behave as lipotoxic lipid species. Amongst them, ceramides and 
sphingosines are considered the “usual pathogenic suspects”. The biochemical processes of 
biosynthesis and remodelling of ceramides/sphingolipids are undoubtedly complex involving at least 
three well-characterised pathways described in detail elsewhere [1, 2]. These biosynthetic pathways are 
highly compartmentalised within the cell, which leads to the formation of discrete organelle lipid pools 
accumulating specific ceramide and other sphingolipids species. Their topographic localisation within 
the cell determines their supplied/targeted structures and also affects their signalling responses to 
extracellular and/or intracellular stimuli. Thus, it is the biochemical repertoire of sphingolipid molecules 
(e.g. sphingomyelin, ceramide, C1P, sphingosine, S1P as well as other complex sphingolipids), but also 





As typically observed in insulin resistant diabetes and also in some cancers, excessive accumulation of 
sphingolipids causes toxicity. In addition to their absolute abundance and localisation, the relative 
proportions of their specific biochemical species is also pathologically relevant. This concept has 
recently been coined as the “sphingolipid rheostat” [9], which refers to the relevance of  the coordinated 
regulation and balance of specific sphingolipids (ceramides, sphingosine and S1P) for the control of 
cellular responses. This concept was originally studied in the field of cell fate and cancer, but recent 
investigation has demonstrated its validity for metabolic pathologies such as cardiovascular diseases 
[10, 11] and diabetes [12]. Therefore, this paradigm needs to be revisited to include new regulators of 
sphingolipid metabolism as well as the paracrine action of some of those sphingolipids [13].  
The dysregulation of the rheostat either by increasing or decreasing specific types of 
sphingolipid species may exacerbate the pathology, may be used as biomarker of phenotypes or stages 
within the natural history of the disease, and could be helpful to identify nosological entities. Thus, 
sphingolipid profiles could be used as diagnostic, prognostic and therapeutic responsiveness biomarkers 
of metabolic stress and disease. 
The current interest on the pathophysiological role of sphingolipids has been sparked by 
enabling technologies such as cellular and in vivo knockout models and improved lipidomic platforms. 
Technologies such as genetic engineering/editing and mass spectrometry have helped to elucidate the 
function of sphingolipid and glycerophospholipid regulated pathways, recognise their direct 
contribution to toxic cellular effects, and have identified new allostatic pathways designed to restore or 
maintain cellular homeostasis. The two most recognised sphingolipid-mediated toxic effects at cellular 
level are mitochondrial and endoplasmic reticulum stress and apoptosis [14, 15]. Another important but 
underestimated target of sphingolipid/ceramide mediated toxicity is the perturbation of 
glycerophospholipids homeostasis and their associated signalling events, the main focus of this 
review. 
Using systems biology, Koberlin [16] and Vonkova [17] have provided new evidence for the 
close bidirectional interaction between sphingolipids and glycerophospholipids. Koberlin et al. have 





a circular network of co-regulated lipids [16]. Their elegant approach has revealed a fundamental inter-
lipid regulatory network that controls membrane lipid composition. Interestingly, these membrane lipid 
perturbations predicted the inflammatory responses in patients derived cells; enabling the functional 
assignment of lipids to specific Toll-like-receptor (TLR) signalling. Moreover, Vonkova and colleagues 
have shown the existence of cooperative (and also a few deterring) interactions between 
phosphatidylinositides (acting as driver ligands), and sphingolipids (in an auxiliary role), that mediate 
the recruitment of PH containing proteins to the membranes in both yeast and higher eukaryotic models. 
Moreover, in many cases, these cooperative events are highly specific and restricted to specific pairs of 
signalling lipids  [17]. Thus, accumulating evidence indicates that both, sphingolipid and 
glycerophospholipid metabolism is essential for cellular membrane dynamics. Both types of lipids 
mutually regulate their biosynthesis and signalling paths within eukaryotic cellular models.  
Our perception after reviewing the subject is that both, sphingolipid and glycerophospolipid 
metabolism are highly connected, integrated and driven in opposed directions, representing a harmonic 
“Ying and Yang” model of regulation contributing to  membrane lipid  homeostasis and lipid signalling 
events. Below, we provide the current experimental evidence supporting the existence of this regulatory 
crosstalk. 
1. Evidence that sphingolipid metabolism is essential for cellular membrane dynamics and 
signalling. 
Sphingomyelins and ceramides are present in the lipid rafts and caveolae domains of the plasma 
membrane. The relative concentration of sphingolipids, phospholipids and cholesterol [18-25] 
determines its biophysical properties varying from gel to liquid-ordered and to liquid-disordered 
structures [26, 27]. Other sphingolipid species, such as sphingosine or ceramide-1-phosphate, are also 
present in membranes at lower concentrations. Despite their low concentration, these lipids play 
essential roles as determinants of membrane dynamics and signalling pathways. For instance, 
sphingosine permeabilises phospholipid bilayers and increases vesicle leakage [28]; S1P modifies the 





is required for the formation of a negative membrane curvature [30] and it is not segregated into lateral 
lipid domains in phospholipid bilayers [31]. 
The use of artificial liposomes and in vitro cellular models have documented how temperature 
[32] and/or other mechanical stresses affect the interaction between ceramides and the other constituents 
of the plasma membrane [33]. There is evidence from these in vitro models that both, quantitative 
(relative percentage) and qualitative changes (length and unsaturation of fatty acid moieties) [34, 35] in 
sphingolipids (mostly ceramides and sphingomyelins) [36-43] perturb the biophysical properties of the 
plasma membrane (e.g. fluidity, lateral pressure and diffusion). These are non-subtle membrane 
perturbations and are likely to compromise metabolite transport and diffusion, receptor signalling, 
sorting and trafficking, formation of pores (e.g. in the outer membrane of the mitochondria [44]) and 
activation of apoptotic stimuli. 
 At physiological levels, SMs stabilise the interactions with sterols in bilayer membranes [45, 
46] and regulate the trans bilayer movement and distribution  of diacylglycerols (DAGs) [47] and 
galactosylceramides [48]. In contrast, ceramides -when in excess- associate with SM/PC and 
destabilise/ displace cholesterol within the membrane (reviewed in [26, 49, 50]). Ceramides facilitate 
the transbilayer lipid movement in membranes, which occurs irrespectively of whether ceramides are 
externally sourced or obtained by metabolising SM via SMases [51]. Additionally, there is evidence 
that ceramides spontaneously translocate (with limited capacity) from the outer to the inner leaflet of 
the plasma membrane [52, 53], which is relevant for signalling and trafficking. The position of 
ceramides in the inner or outer side of the membrane is important given their role promoting plasma 
membrane repair in response to injury [54] and control of exocytosis or endocytosis [55], processes that 
require the involvement of a functional plasma membrane.  
Genetically modified murine models have helped to identify the primary effects on energy homeostasis 
of sphingolipid-related gene ablation. These experiments have also revealed robust compensatory 
mechanisms aiming to maintain cellular and tissue homeostasis, some of them of therapeutic potential. 
For instance, the SMS2KO mouse exhibited a healthy phenotype characterised by impaired fatty acid 





[39]. Alterations in membrane lipid microdomains associated with CD36/FATP1 transporters and 
CAV1 [40] ultimately lead to decreased lipid storage. Conversely, overexpression of sphingomyelin 
synthases, SMS1 and SMS2, caused a pro-atherogenesis phenotype characterised by aggregation of 
lipoprotein particles [56].  Also interesting is the effect of sphingomyelin ablation on cellular signalling. 
Particularly, SMS deficiency or overexpression are expected to change membrane microdomains (lipid 
rafts, caveolae) enriched in SM, affect their biophysical properties and compromise transport, secretion, 
and signalling mechanisms such as apoptosis and cell death [57]. Furthermore, SMS1 and SMS2 
deficiency/overexpression also affect the levels of sphingosine and S1P [58, 59] that could potentially 
act as second messengers. In the light of recent investigations it has been suggested that S1P may 
contribute to the development of insulin resistance in mice [60-63]. Thus, it is tempting to speculate 
that changes in S1P in those models may contribute to their overall phenotype.  
Whereas the in vivo evidence for the crosstalk between sphingolipids and glycerophospholipids 
is still limited, the in vitro models have shown that sphingolipids and glycerophospholipids interact at 
a functional level. Moreover, this crosstalk goes beyond what could have initially been anticipated given 
the relatively marginal structural disruption observed from gain or loss of function genetic experiments. 
These in vitro studies show the direct regulation of glycerophospholipids metabolism by sphingolipids 
by interfering with major phospholipases, such as PLA2, PLC and PLD, releasing lysophospholipids 
and fatty acids that could act as signalling metabolites.  
2. Evidence of the crosstalk between sphingolipid and glycerophospholipid metabolism. 
Beyond the linear lipid biosynthesis pathways, accumulating evidence shows that these pathways 
crosstalk and intertwine with others metabolic networks. These interactions are evolutionary preserved 
in plants, fungi, protozoa, yeast as well as in invertebrates and vertebrates (reviewed in [64]). 
One important crosstalk between sphingolipid and glycerophospholipid metabolism is the metabolic 
pathway modulating the conversion of sphingolipids to glycerophospholipids regulated by the S1P lyase 
recently reviewed by Kihara [65]. Briefly, degradation of S1P and sphinganine (dihydrosphingosine) 





phosphoethanolamine. When these fatty aldehydes are oxidized and converted into palmitoyl-CoA by 
the concerted action of several enzymes, it enters the biosynthesis pathway of glycerophospholipids. 
Recent evidence also suggests that degradation of sphingosine and sphinganine may contribute to the 
biosynthesis of etherlipids (ether analogues of phospholipids) when the activity of the fatty aldehyde 
dehydrogenase (e.g. ALDH3A2) is inactive [66]. This suggests that interlipid conversion may be a 
common allostatic response in pathologies characterised by sphingolipid alterations. Interestingly, this 
lipid interconversion may lead to lipotoxicity as the hexadecenal is able to form aldehyde-derived DNA 
adducts  [67]. The relevance of this in pathophysiological scenarios has not been investigated yet.  
In the same line of evidence, Kondo et colleague have shown that phytosphingosine can also be 
metabolised to odd-numbered fatty acids and incorporated into glycerophospholipids, both in yeast and 
mammalian cells, or alternatively undergo mitochondria oxidation [68]. However, further investigation 
will be required to fully understand the biological significance of this pathway in overall lipid 
homeostasis. 
2.1 Evidence for a cross talk between sphingolipids and phosphatidylethanolamine 
Phosphoethanolamine, the other degradation product of S1P and sphinganine, can enter the CDP-
ethanolamine pathway to generate phosphatidylethanolamine (PE) [69-71]. Moreover, PE can be 
further converted to other glycerophospholipids such as PC and PS, via PEMT and PDSS2 enzymes 
respectively. 
 Proof of this close relationship between sphingolipids and phosphatidylethanolamine is the evidence 
that genetic manipulation of sphingolipids biosynthesis impairs PE homeostasis by limiting substrate 
availability. For instance, the simultaneous ablation of Sphk1 and Sphk2 [72] (the enzymes responsible 
of the phosphorylation of sphingosine to S1P) and the S1P lyase in vivo [72, 73] decreased PE levels 
and accumulated  sphingosines, ceramides and sphingomyelins -as a result of the direct reutilization of 
the sphingosine backbone- [73] These data indicates that the biosynthesis of glycerophospholipids from 
sphingolipids intermediates is essential for the degradation of sphingolipids [74] and that perturbations 





significance for the survival of the protozoan parasite leishmania being the major route for ethanolamine 
synthesis [75]. 
Additional evidence showing that sphingolipid metabolism affects glycerophospholipid pools comes 
from studies showing that ceramides also inhibit the CDP-ethanolamine 1,2 diradyl-sn-glycerol 
ethanolamine phosphotransferase (EPT) and reduce the levels of PE [69, 76]. Moreover, several in vitro 
and in vivo models of impaired biosynthesis of ceramides have shown both quantitative [16] and 
qualitative changes in the pools of PEs [43, 77] suggesting the presence of compensatory mechanisms. 
Whether this opposed direct action of ceramides vs. S1P regarding PE metabolism is part of a regulated 
homeostatic rheostat is at the present moment unknown.  
Intriguingly, similar to PC (see section below), PE contributes to the biosynthesis of ethanolamine 
containing analogues of SM [78]. Thus, it is also conceivable that PE levels may limit the biosynthesis 
of specific sphingolipid species, in the same way that PCs do. 
2.2 Sphingolipid mediated inhibition of phosphatidylcholine biosynthesis. 
Short chain ceramides but not their structural analogues dihydroceramides [79], prevent the 
biosynthesis of PCs by inhibiting the enzyme CCT [76, 80-82]. Inhibition of CCT requires activation 
of cPLA2 and subsequent release of lysophosphatidylcholine (LPC) [83]. CTT activity and mRNA 
gene expression is also repressed by sphingosine [84]. Interestingly, the inhibitory effect of sphingosine 
on CCT is reversed in the presence of other glycerophospholipids such as PS, PI and PG [85].  
The inhibitory effect of ceramides on PC biosynthesis is tightly controlled and apparently 
independent of the source of ceramides. Thus, in vitro experiments in lung epithelia overexpressing 
ceramide synthase 5 (CerS5) and/or sphingomyelinase (SMase) have shown an additive effect 
mediating the inhibition of the biosynthesis of phosphatidylcholine. Conversely, PC biosynthesis is 
stimulated when Cers5 is downregulated by SiRNA [86]. These data suggest that the PC biosynthetic 





Similarly, SM analogues also inhibit the translocation and activation of CTT [87, 88].  Thus, 
the impairment in PC biosynthesis resulting from increased level of ceramides may be relevant to 
disease pathogenesis and has been proposed as one of many mechanisms for how aSMase may 
contribute to steatohepatitis [89]. Conversely, glycosylceramides have been shown to activate CTT as 
observed in in vitro models of Gaucher disease [90].  
In line with these findings, global lipidomic analysis has lent further support to the existence of 
a solid crosstalk between sphingolipids and PC. For instance, the knock-down of sptlc2 in RAW264 
macrophages increases the levels of PC [16]. Similarly, the total knock-out of sptlc123 in Huh7 
hepatocytes results in increased phospholipids with an enrichment in PC species [91]. Paradoxically, 
the sptlc2 heterozygote  [39] and the heart specific sptlc2 KO [92] mice exhibited a decrease in the  PC 
levels as well as qualitative changes in the FA of the PC fraction. These data suggest that the changes 
observed in the PC pools in these models are likely secondary homeostatic responses directed to 
preserve cellular or tissue viability.  
Moreover, sphingolipids also regulate the pool of PCs through indirect mechanisms. An 
illustrative example of this is the influence of SM levels on the hydrolysis of PC pools from VLDL, 
LDL and HDL lipoproteins by hepatic lipase (HL) (see also section 5.2). Thus, SM depletion stimulates 
the hydrolysis of PC (mainly PUFA-PC) as well as TG, indicating that SM acts as an inhibitor of HL 
[93]. Another effect relates to the activation of the ABCB4 receptor expressed in the canalicular 
membrane of hepatocytes whose function is to export PC into the bile. In this regard, Zhao and 
colleagues have shown that the cellular content of SM is critical for ABCB4 to facilitate the efflux of 
PC, opposite to the effects of other members of the ABC family such as ABCB1 [91]. 
PCs also reciprocally regulate sphingolipid metabolism. Examples of this regulation include: 
a) the activity of PCs acting as phosphocholine donors for SM biosynthesis [94-97]; b) the fact that 
choline deficient media/diets [98] or that pharmacological inhibition of choline kinase [99], both impair 
the synthesis of SM while concomitantly increasing ceramide levels. Conversely, the action of SMase 





generation of phosphatidylcholine [100]. Altogether these data strengthen the concept of a strong co-
regulation between PC and SM biosynthetic and metabolic pathways. 
2.3 Evidence for a crosstalk between sphingolipids and phosphatidylserine. 
Serine is a common component of both PS and ceramides, suggesting that both types of lipids 
may be metabolically connected. This biochemical link has been confirmed by in vitro where labelled 
serine originated from PS was identified in ceramides [101]. Moreover, sphingosine, S1P and lyso-
sphingomyelin increase the biosynthesis of PS and block the conversion of PS to PE by decarboxylation 
[102, 103] mediated by a PKC independent mechanism [104, 105]. In support of this regulatory loop, 
the ablation of sptlc2 gene in RAW264 macrophage caused the expected impairment in the de novo 
biosynthesis of ceramides but also decreased the levels of PS.  Similarly, the elevation of SM mass by 
different mechanisms  leads to the depletion of the PS pool from the plasma membrane [106] leading 
to mislocalisation of k-ras [37], this was prevented by inhibition of SM synthesis suggesting the 
existence of a concerted mechanism to regulate the levels of both lipids in the plasma membrane. 
In addition to SM, other sphingolipids also affect the location of PS in   the plasma membrane 
as well as some of the biochemical processes regulated by PS. Thus, the ceramides generated by 






of PS and also contribute to the translocation of PS to the outer membrane, a requirement for 
platelet secretion and thrombus formation [107]. Other sphingolipids such as sphingosines, due to their 
positive charge, prevent the binding of calcium to PS enriched vesicles [108-110] and/or negatively 
modulate substrate phosphorylation by PKC by directly competing with PS [111, 112]. This evidence 
indicates that ceramides facilitate PS biosynthesis and optimise cellular location, whereas other 
sphingolipids elicit a negative effect on PS homeostasis. 
It is worth noting that a recent investigation in the forebrain of CerS6KO mice [113] has shown the 
paradoxical increase in PS levels. This may be interpreted as against ceramides having a positive effect 
on the PS pool. Nevertheless, in this model there is a specific depletion of C16:0 ceramides rather than 
a global depletion, and as the molecular mechanism to support this finding is unknown, further research 
is required. 
 In terms of our ying/yang concept, the yang of this regulation is that phosphatidylserine 
reciprocally modulates sphingolipid metabolism. For instance, PS increases the activity and 
translocation of sphingosine kinase to membranes [114, 115]  and also activates enzymes involved in 
the degradation of complex sphingolipids [116, 117] . Whether PS interferes with the activity of SMase 
is less clear as some studies have shown that PS inhibits PKC mediated activation of neutral SMase 
[118], whereas others indicate that PS stimulates neutral  [119] and alkaline [120] SMSase activities. 
PS also reverses some of the negative effects of sphingolipids on enzymatic activities. PS (as 
well as PI but not PC) reverses sphingosine mediated inhibition of transmembrane protein 
tyrosylprotein sulfotransferase (TPST), the enzyme that catalyzes the sulfation of tyrosines. Despite the 
molecular mechanism not being well characterised,  the authors concluded that the positive charges of 
sphingosine and a long alkyl chain are fundamental for impairing the affinity of the protein-substrate 
and that PS is able to reverse that inhibition in a competitive manner [121]. 
 Similarly, PS also reduces the inhibitory effect of sphingosine on the autophosphorylation of 
the insulin receptor tyrosine kinase [122]. In this regard, it has been suggested that the high affinity for 





investigations suggest that acidic phospholipids, such as PS, may prevent the interaction of sphingosine 
with the targeted proteins. Given that sphingosine inhibits other kinases such as SRC kinase [123], it is 
conceivable that this competitive interaction between sphingosine and PS may be common  in other 
similar kinases. Further research will be needed to evaluate the biological significance of this 
competitive interaction. 
2. 4 Bidirectional Crosstalk between Sphingolipid metabolism and Platelet Activating Factor.  
 Platelet Activating Factor (PAF) is an ether-glycerosphospholipid important for immune cell 
activation. The first insight for an interaction between PAF and sphingolipid biosynthetic pathways 
came from the discovery of a CoA independent transacetylase that mediates the transfer of an acetyl 
group from PAF in the synthesis of N acetylsphingosine [124-126]. More recently, we have learned that 
S1P promotes PAF synthesis [127, 128] and modulation of cell chemotaxis and inflammatory responses 
in immune cells. Conversely, PAF increases SMase activity and facilitates the generation of ceramide 
microdomains, which are important for inflammation, apoptosis, activation of eNOS in EC cells [129], 
development of pulmonary oedema [130], and the activation of the enzyme scramblase that facilitates 
the exposure of PS in the outer membrane [131]. 
3. Sphingolipids modulation of phospholipid biosynthesis via SREBP activation.  
How sphingolipids regulate the biosynthesis of phospholipids at a molecular level is a key question. 
SREBPS are important mediators of the biosynthesis of fatty acids, cholesterol and TGs. SREBPS also 
regulates the levels of phosphatidylcholines by regulating the expression of pcyt1a (the gene that 
encodes CTT) at transcriptional and posttranscriptional mechanisms level [132, 133]. SREBPS may 
also indirectly increase pcyt1a expression and activity secondarily to the concomitant biosynthesis of 
fatty acids. Genome-wide analysis of SREBP1 binding in mouse liver has shown the presence of 
putative SRE motifs in the phosphatidylinositol synthase gene [134], suggesting that the regulation by 
srebp1 might not be restricted to PC biosynthesis. This concept is further reinforced by novel research 





Sphingolipids control SREBP1 cleavage and activation by different mechanisms: a) the breakdown of 
sphingomyelins to ceramides in the plasma membrane displaces cholesterol to intracellular 
compartments where cholesterol represses the cleavage and activation of srebp1 and 2 [137]. Additional 
evidence indicates that high levels of ceramides resulting from SM hydrolysis inhibit SRE mediated 
gene transcription independently of changes in intracellular cholesterol trafficking through a 
mechanism not yet defined [138] and  b) S1P stimulates SREBP1 cleavage and nuclear translocation 
via a S1P receptor [139].  
Sphingolipids also regulate SREBP1 expression. For instance, ceramides have been reported to 
increase the levels of the precursor SREBP and decrease the levels of mature SREBP [140]. Moreover, 
accumulation of SM (either from external origin or as a result of the inhibition of SMase) represses 
srebp1 expression via a caveolin and Ras-ERK-MAPK-CREB signalling pathway in adipocytes [141]. 
Accordingly, dietary administration of sphingomyelin decreases hepatic lipid levels due to inactivation 
of the LXR-SREBP1 pathway [142]. The potential pathophysiological relevance of these findings is 
highlighted by a recent study showing that increased levels of SMs are associated with decreased levels 
of srebp1 mRNA in the adipose tissue of obese women [141].  
Altogether, this indicates that sphingolipids may regulate lipid homeostasis (including PC 
biosynthesis), by controlling both the expression and activation of SREBP1. This may be of particular 
relevance in tissues such as liver and adipose tissue where SREBP1 is an important regulator of lipid 
synthesis, and where its dysregulation contributes to the development of NAFLD and obesity associated 
adipose tissue dysfunction. 
4. Sphingolipids interfere with phospholipid mediated signalling.  
4.1 Sphingolipids modulate the biosynthesis and activity of phophatidylinositols.  
Compared to the robust effect of sphingolipids on other phospholipids, the evidence that 
sphingolipids may interfere with the de novo biosynthesis of phosphatidylinositol phospholipids in high 
eukaryotic cells is still preliminary. However, it is known that the small subunit of the serine 





protein [144]. Thus, this protein could be a pivotal signal co-regulating both the synthesis of ceramides 
and the biosynthesis and remodelling of PI species. Of relevance, we have recently observed that in 
adipocytes engineered with a knock down of the DEGS1 enzyme, the enzyme controlling the final step 
of the de novo biosynthesis of ceramides by promoting the desaturation of dihydroceramides to 
ceramides [79], results in decreased levels of glycerophospholipids, specially etherlipids and 
phosphatidylinositols. Whether the downregulation of these lipids is the result of the decreased 
ceramide pool, increased dihydroceramides, or alternatively occurs secondarily to homeostatic changes, 
is currently under investigation (Rodriguez-Cuenca, unpublished).  
4.1.1 Sphingolipids modulate the synthesis and signalling mediated by Phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2). 
In terms of its concentration, phosphatidylinositol-4,5-bisphosphate is a relatively minor 
phospholipid in cell membranes. However, it is functionally important as a substrate for signalling 
proteins. Sphingosine - at low doses - activates the enzyme phosphatidylinositol-4 kinase that converts 
PI into PI4P. However, this reaction is repressed when sphingosine is present at high concentrations as 
a result of the biosynthesis of sphingosine phosphate [145, 146]. Additionally, gangliosides also activate 
PIP5K and increase PI(4,5)P2, which contributes to the inflammatory response via NFkB activity [147]. 
Thus, these data strongly support that sphingolipids both regulate the biosynthesis of PI derivatives and 
interfere with their signalling events.  
Quantitative changes in the sphingolipid pools of the plasma membrane are 
pathophysiologically relevant as they perturb the microenvironment and compartmentalization of 
PI(4,5)P2, and compromise the recruitment of specific signalling proteins to the membrane. Some 
illustrative examples of this link between sphingolipids and impaired signalling are: a) increased levels 
of ceramides resulting from the ablation of Ceramide Kinase (CERK) directly impair PI(4,5)P2 
processing by PLC and prevent the recruitment of photoreceptors in drosophila cells [148]; b) depletion 
of SM in otherwise typically rich domains, disperse PI(4,5)P2 and inhibit the recruitment of GTPases 





Moreover, sphingolipids directly compete but also occasionally synergise with the effect 
exerted by PI(4,5)P2 on different enzymes and proteins. For instance, whereas PI(4,5)P2 facilitates the 
phosphorylation of ERM proteins in the plasma membrane (which plays a crucial role in the 
organization of membrane domains through interaction with transmembrane proteins and the 
cytoskeleton), ceramides exert the opposite effect and repress ERM phosphorylation by activating 
phosphatases [150]. Another example of the opposing effects between sphingolipids and PI(4,5)P2, 
comes from studies on phospholipases (see section 5). Here, ceramides inhibit PLD activity by 
competing for its catalytic core with PIP2 (activator) [151]. Similarly, SMs also compete -against PIP2- 
and repress PLCδ1 [152]. However, in its phosphorylated form, C1P, does not compete but actually 
synergises with PIP2 activation of PLA2G6 by modulating their interaction with PC in the membrane, 
and/or by increasing the catalytic efficiency respectively [153]. In this regard, an interesting finding in 
yeasts, which are theoretically transferable to higher eukaryotic cells, is that PI(4,5)P2 (as well as other 
phosphoinositides such as PI(3,5)P2, PI(5)P, PI(3)P) cooperates with and in a few cases interferes with 
a variety of sphingolipids such as dihydroceramides, dihydrosphingosines in targeting PH domains to 
membranes [17].  
4.1.2 Sphingolipids modulate the signalling mediated by Phosphatidylinositol 3,4,5-trisphosphate 
(PI(3,4,5)P3). 
Phosphatidylinositol 3,4,5-trisphosphate is the product of phosphorylation of 
phosphatidylinositol (4,5)-bisphosphate by PI3K and localises to the plasma membrane. One of the key 
signalling events regulated by PI3K is the activation of AKT. The activation of PI3K converts PI(4,5)P2 
into PI(3,4,5)P3 and facilitates the binding of PI(3,4,5)P3 to the pleckstrin homology domain of protein 
kinase B/AKT. This induces both a conformational change and translocation as well as further 
activation by Ser473 phosphorylation via PDK1. Like AKT, PDK1 also possesses a 
PI(3,4,5)P3/PI(3,4)P2 binding Pleckstrin homology domain (PH) domain, necessary for PDK1-mediated 
phosphorylation of Thr308 and full AKT activation [154-159]. 
 From the pathophysiological point of view, one of the most studied lipotoxic effects of 





PI3K/AKT [160, 161]. The mechanisms through which ceramides interfere with PI3K signalling 
include the PPA2 mediated dephosphorylation of AKT Ser473 [160, 162-165] and the inhibition of the 
recruitment of CAV1 to PI(3)K-associated receptor complexes within lipid raft microdomains [166]. 
Of note, ceramides disable the binding of PI(3,4,5)P3 to the plecktrin homology domain of PKB/AKT, 
an effect mediated by activated PKCz and the subsequent phosphorylation of PKB/AKT [160, 162-164, 
167]. Through this mechanism, ceramides impair the activation and translocation of insulin induced 
AKT kinase [168] and contribute to insulin resistance. Interestingly, the long chain ceramides directly 
interact with the catalytic domain of the PI3KC2b subunit, which disturbs its compartmentalization and 
suppresses its activation [169]. Additionally, the negative effect of ceramides on PI(3,4,5)P3 related 
signalling also involves other domains that impair the translocation of certain PI(3,4,5)P3-binding 
proteins such as GRP1 (general receptor for phosphoinositides-1), even in the presence of PI(3,4)P2 or 
PI(3,4,5)P3 [170].  
S1P activates the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway via S1P 
receptors (coupled with Gi) and modulates a variety of cellular processes including cell proliferation, 
migration and stress response [171-173]. This contrasts with the observation that S1P reduces the ability 
of insulin to induce AKT phosphorylation via S1P2 receptor in muscle cells [63, 174] and highlights 
the differences amongst the three classes of PI3K members (class I that produces PI(3,4,5)P3, and class 
II and III that produces PI(3P) and the cell specific peculiarities of similar signalling pathways. 
In summary, the above data suggest that sphingolipids interfere with PI derivatives by affecting 
their biosynthesis and metabolism, and by competing with their signalling processes. This supports the 
concept that lipotoxic effects mediated by sphingolipids involve physicochemical changes in 
membranes as well as impairments in both signalling and metabolic reactions and contributes to 
common disorders such as insulin resistance and diabetes. The impact of sphingolipids on other 
phosphatidylinositol related signalling events in the context of disease has not yet been elucidated. 





There are also reciprocal effects between phosphatidylinositol metabolites and sphingolipid 
metabolism. This is particularly relevant in yeast, where PI provides phosphoinositol for the generation 
of inositolphosphorylceramides [175]. In addition to this direct metabolic link found in yeast, there is 
also a regulatory mechanism mediated by Pkh1, Torc2 and Ypk1 [176-178] that coordinates the 
biosynthesis of PI/phosphoinositides and sphingolipids. This co-regulation is essential to adjust the 
membrane lipid composition and maintain its integrity particularly in response to environmental stress.  
In higher eukaryotic cells for instance, PI(3,5)P2 is a potent and specific inhibitor of acid 
sphingomyelinase (aSMase) and therefore blocks the generation of pro-apoptotic ceramides [179-181]. 
However, phosphatidylinositol ether lipid analogues exert the opposite effect inducing apoptosis via 
activation of SMase and concomitantly increase in ceramide levels [182]. Another mechanism 
mediating this crosstalk is illustrated by PI(4,5)P2, which has been shown to interact with the PH domain 
of ceramide kinase (CERK) and regulate its location to the Golgi and plasma membrane targeting. The 
localisation of CERK is important as it determines the levels of C1P in the plasma membrane [183]. 
Additionally, PI(4,5)P2 and PI4P have been shown to modulate the activity of Sphingosine kinases 1 
and 2 [184, 185]. 
Another example of multifaceted crosstalk between sphingolipids and PI derivatives is that 
PI4P - generated by a PI4 kinase IIIbeta- regulates the flow of ceramides between the ER and Golgi, 
and favours the synthesis of sphingomyelin by binding to the N-terminal pleckstrin  homology domain 
of a ceramide transport protein (CERT) [186, 187]. This process is regulated by cholesterol as it affects 
the activity of PI4KIIa- by altering its membrane microenvironment- and by facilitating the recruitment 
of CERT to the Golgi where it promotes SM biosynthesis [188]. Additionally, the availability of PI4P 
synthesised by PI4 kinase IIIbeta and PI4KIIa also contributes to the delivery of beta-
glucocerebrosidase (an enzyme relevant for the degradation of glucosylceramide) to the lysosome 
[189].  
Overall, these examples show that both sphingolipids and PI derivatives, exert bidirectional 
regulatory roles in signalling. Intriguingly, the existence of cross-regulation between these lipid families 





each other lipid species. This raises the possibility that pathologies characterised by defects in 
sphingolipid metabolism may benefit from strategies targeting phosphatidylinositol metabolites and 
viceversa. 
5. Sphingolipids modulate phospholipid composition and signalling via regulating phospholipase 
activity. 
In addition to the direct effect of sphingolipids on the biosynthesis of glycerophospholipids and their 
derivatives, there is also evidence that modulation of signalling pathways by sphingolipid is directly 
dependent on the metabolisation of phospholipids by major phospholipases as outlined below. 
5.1 Sphingolipids regulate Phospholipase C (PLC) activity.  
Phospholipase C includes a group of lipases that catalyse the hydrolysis of the linkage between 
glycerol and phosphate in glycerophospholipids, releasing DAG and choline-P from PC, and inositol 
1,4,5 triphosphate from PIP2. SM as well as glycosphingolipids have been reported to directly inhibit 
PLCδ1 and PLC through a mechanism dependent on the chain length and unsaturation index of the 
fatty acid moieties [190-193]. Conversely, in liposome based studies, sphingosine has been described 
to activate PI-PLC by direct physical interaction with PLC- in a calcium dependent manner [194, 195]. 
Alternatively, sphingosine as well as S1P were reported to activate PLC, enhancing PI turnover and 
calcium mobilization via G protein interaction [196-198], which supports an extracellular action of S1P. 
The discovery of S1P receptors (for a detailed review see [199, 200]) as mediators of such effects was 
described later on [201]. In this regard, the coupling of several S1P receptors (S1P1-4) to particular G 
proteins (Gi and Gq) has been demonstrated to activate PLC in a variety of cellular models [202, 203]. 
In the same line of evidence, C1P also activates PI-PLC and increase the levels of S1P [204], 
unfortunately the precise molecular mechanism is currently unknown. 
An example of sphingolipids modifying PLC activity occurs in response to HDL associated 
sphingolipids. HDL in addition to glycerophospholipids, steroids, triacylglycerides and cholesteryl 
esters carries several sphingolipids including sphingomyelin, ceramides and lysosphingolipids [205] 





Among them, S1P is the best characterised in relation to their impact in vascular biology [207]. Other 
biologically active lysophospholipids in HDL are lysosulfatide and sphingosylphosphorylcholine. 
Interestingly, these two lysophingolipids trigger specifically PI-PLC activation and stimulate cell 
proliferation in contrast with the Apo AI activation of PC-PLC associated with induced cholesterol 
efflux [208]. Here, authors suggested that these lysophingolipids could account for some anti-
inflammatory effects mediated by HDL. These data support the concept that qualitative changes in the 
HDL sphingolipidome modify the physico-chemical properties of lipoproteins, impact signalling 
cascades mediated by PLC (as well as other lipases and phospholipases) and ameliorate or exacerbate 
the atherogenic risk. In this regard, despite the evidence in rodent models that overexpression 
/repression of SMS increase/decrease the atherogenic potential respectively [56, 58] the contribution of 
secondary changes in the glycerophospholipids and their metabolites was not evaluated. 
Another revealing example of how sphingolipid metabolism interacts with 
glycerophospholipids has been shown for the intestinal alkaline SMase. Besides acting on SM, the 
alkaline SMase also directly hydrolyses PAF working as putative phospholipase C, removing the 
phosphocholine head group and generating 1-O-alkyl-2-acetyl-sn-glycerol. Interestingly, the hydrolysis 
of PAF and SM can be counterregulated by the presence of SM and PAF respectively [209]. If this 
apparent promiscuity is part of a  regulatory mechanism that controls the levels of specific 
glycerophospholipids by different members of the sphingolipid family and enzymatic repertoire will 
need to be addressed in the future. 
5.2 Sphingolipids regulate Phospholipase D (PLD) activity.  
Phospholipase D catalyses the cleavage of the phosphodiester bond of structural phospholipids 
and releases phosphatidic acid (PA), a well-established second messenger. Sphingosine and 
sphingosine-1-phosphate, both activate PLD and directly compete with the inhibitory effect exerted by 
PE and PC [210-215], through both PKC dependent and independent mechanisms [216]. One of the 
mechanisms described for S1P as an activator of PLD is via activation of the SP1 receptor, as suggested 





Sphingolipids also exert inhibitory effects on PLD. Ceramides for example inhibit 
phospholipase D, through a change in membrane biophysical properties which impair PKC 
translocation to the membrane, a required step for PLD activation [218-223]. Moreover, ceramides also 
repress the transcription of PLD mRNA in several cellular models [224-226]. This inhibitory effect of 
ceramides on PLD activity/expression is pathophysiologically relevant as indicated by its effects 
promoting: a) insulin resistance in hepatocytes [227], b) senescence [228] and c) apoptosis in granulosa 
cells [229]. However, the inhibitory effect of ceramides on PLD has been contested by some studies 
showing that it is the conversion from SM to ceramide in lipid rafts which activates PLD [230]. 
Therefore, it cannot be excluded that the activation of PLD is driven by the secondary conversion of 
ceramides to other bioactive sphingolipids. 
Conversely, the PA released upon PLD activation regulates sphingolipid homeostasis. For 
instance, PA inhibits C1P stimulated macrophage migration [231], facilitates the translocation of 
Sphingosine kinase1 to membrane compartments [232], and modulates the activation of protein 
phosphatase 1 by ceramides [233]. Recently, Demirkan et al. identified a strong association between a 
SNP in PLD2 (rs12051548) and the ratio of sphingomyelins SM(d18:1/23∶0) / SM(d18:1/16∶1) in a 
GWAS study [234].  Nevertheless, the possible molecular mechanism responsible for such interaction 
is currently unknown. Globally considered, these data strongly support the existence of a bidirectional 
cross talk between sphingolipids and derivatives of glycerophospholipids that determine the 
biochemical repertoire and concentrations of second messengers.  
5.3 Sphingolipids regulate phospholipase A2 activity.  
 PLA2 enzymes play an important role in lipid mediated inflammatory processes, signalling and 
phospholipid remodelling. Specifically, PLA2 phospholipases hydrolyse the bond at the second carbon 
group of glycerol, releasing the fatty acid moiety located in the sn2 position (e.g. arachidonic acid) and 
the corresponding lysophospholipid [235]. Several families of enzymes exist according to their 
dependence on calcium, location, substrate preference, specific roles in signalling, immune response 





5.3.1 Sphingolipids regulate cytosolic and calcium-independent phospholipase A2 
Ceramide, ceramide-1-phosphate, sphingosines and other complex sphingolipids regulate the 
activity of cytosolic PLA2 (cPLA2) and the release of arachidonic acid (AA) in many cell types. For 
instance, C1P, sphingosine and lactosylceramide directly bind to the calcium binding (C2) domain of 
cPLA2a (PLA2G4A), facilitating its translocation from cytosol to Golgi (into PC rich areas) and 
activating the release of AA from substrate phospholipids [236-244]. This phenomenon is essential for 
biological processes such mast cell degranulation [245], stimulation of cell adhesion pathways between 
monocytes and endothelial cells [246], and vasodilation [247]. Most importantly, they contribute to the 
activation of prostaglandin biosynthesis in response to calcium and inflammatory agonists such as 
TNF, ILβ1 [248, 249]. Another much less studied cPLA2, the plasmalogen selective PLA2, seems to 
be activated by ceramides in the brain [260, 261]. Interestingly, recent investigations in the liver  of 
alcohol-dependent patients have proposed the activation of cPLA2 as a potential mechanism linking the  
increased levels of ceramides as consequence of the high activity of  aSMase and the  increase in hepatic  
LPC observed in that subjects [250]. Interestingly, increased levels of both LPC [251, 252]  and 
ceramides [253]  have been also shown in NAFLD patients. Whether the increase in LPC is due to a 
ceramide mediated activation of PLA2 or part of secondary homeostatic response/or lipotoxic insult 
will required further research. 
In addition to the direct activation of cPLA2 by ceramides and derivatives, cPLA2 is also 
activated through indirect mechanisms via PKC activation [254, 255]. Moreover, cPLA2 is activated 
by C1P via JNK [256]. This latter mechanism has been considered as a cellular strategy for recycling 
structural phospholipids into energy generating substrates in CHO cells [257]. S1P also activates 
PLA2G6, releasing AA and LPC, which subsequently activate TRP5 cationic channels in HEK293 cells 
[258]. Conversely, other members of the sphingolipid family exert deterring effects on phospholipase 
A2 activity. For example, SM decreases the activity of cPLA2 by disturbing its binding to 
glycerophospholipids, which impairs the release of AA [259, 260].  Gangliosides are another example 





Despite the fact that most of the research focused in PLA2 and ceramides has aimed to 
investigate the signalling/inflammatory events mediated by the release of fatty acids (e.g arachidonic 
acid) and lysophospholipids, it is conceivable that others aspects of PLA2 biology such as their role in 
the remodelling of phospholipids in partnership with LPLATs (lands’ cycle) will be also affected. This 
is an area which our lab is currently exploring in relation to obesity and associated comorbidities. 
5.3.2 Sphingolipids also regulate Secretory PLA2 
  Similarly to their effect on cPLA2, ceramides modify the fatty acid specificity exhibited by 
different secretory phospholipases by inducing structural defects in membrane bilayers [263, 264]. 
Additionally, ceramides mediate the TNF induced upregulation of sPLA2 (and cox2) in mesangial 
cells through NFκB activation and increase production of PGE2, strongly suggesting that this pathway 
is important in the pathogenesis of renal injury [265]. 
 What could be considered the “yang” effect on this occasion would be SM mediated inhibition of the 
activity of secretory phospholipase A2. This has been shown for sPLA2-V and results in the reduction 
of the release of AA [241, 266]. SM may also modulate the binding of PLA2 to membranes, a process 
that is highly dependent on membrane cholesterol levels [267-269]. 
The opposed effect of ceramides and sphingomyelins on the activity of sPLA2 is of biological 
relevance as it affects the clearance and metabolisation of lipoproteins. When HDL and LDL are 
enriched with exogenous long chain ceramides and/or ceramides obtained from the degradation of the 
SM pool, this stimulates the activity of sPLA2V [270-272], which facilitates the release of fatty acids. 
This effect is important as it forms cholesteryl esters in macrophages [273] and promotes aggregation 
and fusion of LDL [274]. As before, SMs exerts the opposite regulatory effect by inhibiting several 
secretory PLA2s even in the presence of oxidised phospholipids, which are well known activators of 
PLA2s [270-272].  
Globally considered, these data indicate that the balance between the ceramide and SM pools 





as well as regulators of oxLDL-induced cholesterol esterification and therefore should be considered 
modulators of the atherogenic properties of lipoproteins. 
5.3.3 Phospholipase A2 reciprocally modulates sphingolipid metabolism. 
There is evidence that certain PLA2s exert a regulatory role on sphingolipid metabolism. For 
instance a) The activation of iPLA2b (PLA2G6) during ER stress seems to activate neutral 
sphingomyelinase and promotes the generation of ceramides, causing mitochondrial dysfunction and 
activating of mitochondrial apoptotic pathways [275, 276], b) another example is pancreatic 
phospholipase A2 (sPLA2IB) which stimulates the expression of neutral sphingomyelinase and acid 
ceramidase via a sPLA2 receptor [277]; in this regard, these phospholipases regulate the production of 
lipid mediators by regulating the expression of key enzymes in phospholipid and sphingolipid 
metabolism. All together, these studies support the existence of a closely regulated bidirectional feed-
back system between sphingolipids and PLA2s.  
Concluding remarks 
Here we have brought together the biochemistry of sphingolipids and glycerophospholipids and 
identified current evidence supporting the existence of a bidirectional crosstalk between them. Its 
importance stems from the fact that their dysregulation can influence the progression of metabolic 
diseases. Despite the literature supporting the association between dysregulated levels of sphingolipids 
and profound changes in glycerophospholipid species at multiple levels, there is little knowledge about 
how these perturbations occur and how they may contribute to the metabolic lipotoxic burden exerted 
by sphingolipids at a cellular, tissue or organismal level, and more importantly how these changes 
specifically contribute to disease models.  
Future studies 
The development of new and more precise high-throughput analytical tools in the field of lipid 
biochemistry in combination with other disciplines such as biophysics, will expand our understanding 





organelles. These “new technological windows” should provide a more detailed picture of the existence 
and relevance of the bidirectional crosstalk between sphingolipids and glycerophospholipids.  
The development of appropriate bioinformatics tools for data analysis is also essential to integrate 
their heterogeneity into workable testable models. The recent identification by Bjorkolm and colleagues 
of several sphingolipid binding motifs in mammalian membrane proteins using a probability algorithm 
(MOPRO) [278] will facilitate the identification of new targets of sphingolipid action. Interestingly, 
among the 672 novel candidates identified there are genes relevant for lipid homeostasis such as scap 
(a regulator of srebp1), and mboat1 and mboat2 (remodelling of glycerophospholipids). In the same 
line of evidences, the recent identification of 234 new candidate ceramide binding protein fragments by 
cDNA display and deep sequencing [279] reveals the presence of important genes for both sphingolipid 
and glycerophospholipids metabolism such as asah1 (acid ceramidase) and mboat7 
(lysophosphatidylinositol acyltransferase) and ptgds (prostaglandin d2 synthase). We envisage an active 
phase of experimental validation of those candidate genes and others that will fuel our understanding 
of the complex crosstalk between sphingolipids and glycerophospholipids biology. 
We believe that the use of genetically modified models to selectively increase or decrease pools of 
specific subsets of sphingolipids in a particular time/spatial frame (conditional tools) and in a precise 
organ (tissue specific) will help to dissect the relevance of sphingolipid related lipotoxicity on global 
lipid homeostasis and metabolism. These experimental models will assist in the understanding of the 
abnormal lipid profiles observed in multiple metabolic diseases such as obesity and insulin resistance, 
where both sphingolipids and glycerophospholipids are disturbed, and where, currently, it is challenging 
to specifically define a causative role for the changes in lipotoxic species (e.g. increase ceramides in 
insulin resistance models). 
 Globally considered, we are optimistic that with the power of new enabling technologies 
elucidating the regulatory networks controlling sphingolipid and glycerophospholipids homeostasis, 






NB. During the review of this manuscript Matsuzaki et colleagues  showed that cardiolipin bind to 
Ceramide kinase and regulate its activity and C1P levels in vitro [280], the pathophysiological 
consequences of such interaction need to be elucidated. 
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Figure 1. Structure of the major sphingolipids [A] and glycerophospholipids [B]. 
Figure 2. Schematic representation of some of the mechanisms described for sphingolipid interaction 
with glycerophospholipid metabolism. [A] Modulation of plasma membrane dynamics. [A] S1P lyase 
pathway [C] Phosphatidylinositides biosynthesis and modulation of enzyme/receptor actions by 
sphingolipids. [D] Interaction with PLC, PLA2 and PLD activity. Cer reads for ceramides, SM reads 
for sphingomyelin, and S reads for sphingosine and S1P reads for sphingosine-1-phosphate.  
Figure 3.  SREBP transcriptional and post-translational regulation: SREBP1 activity/inhibition is 
regulated depending on the environmental demands of the cells. Increase levels of ceramides has been 
shown to alter transcriptional levels of srebf1 as well as impair the  maturation of SREBP1 in ER-Golgi 
(see text for additional details). 
Figure 4.  Summary of  key references reporting direct effects of sphingolipids on glycerophospholipid 
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Sphingolipids in general and ceramides in particular, contribute to pathophysiological mechanisms by 
modifying signalling and metabolic pathways. Here, we present the available evidence for a 
bidirectional homeostatic crosstalk between sphingolipids and glycerophospholipids, whose 
dysregulation  contributes to lipotoxicity induced metabolic stress. The initial evidence for this crosstalk 
originates from simulated models designed to investigate the biophysical properties of sphingolipids in 
plasma membrane representations. In this review, we reinterpret some of the original findings and 
conceptualise them as a sort of “ying/yang” interaction model of opposed/complementary forces, which 
is consistent with the current knowledge of lipid homeostasis and pathophysiology. We also propose 
that the dysregulation of the balance between sphingolipids and glycerophospholipids results in a 
lipotoxic insult relevant in the pathophysiology of common metabolic diseases, typically characterised 









cytidylyltransferase  A,  [CERK]  Ceramide  Kinase,  [C1P]  Ceramide‐1‐phosphate,  [CerS]  Ceramide 
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In the context of common metabolic diseases such as obesity, diabetes or non-alcoholic fatty 
liver disease (NAFLD), the concept of “lipotoxicity” refers to the inappropriate ectopic accumulation 
of lipids in non-adipose organs causing metabolic stress and dysfunction. Lipotoxicity in liver, skeletal 
muscle, heart, pancreas or brain has been identified as an important pathogenic contributor to their 
metabolic dysfunction. Lipotoxicity can operate at multiple levels spanning from cellular to organ levels 
and involves a repertoire of characteristic biochemical mediators. The severity of the lipotoxic insult is 
modulated by the specific cellular genetic vulnerability to the toxicity induced by lipids. When at 
physiological concentrations, most of these lipid species exert important physiological functions that 
contribute to structural, signalling or cellular homeostasis. Hence, these lipids per se only become toxic 
when: a) they accumulate in excessive quantities as a result of exacerbated biosynthesis and/or impaired 
turnover; b) they exhibit distorted qualitative properties (e.g. both biologically or chemically induced) 
and/or c) when their spatio-temporal location in the cell is atypical  (being in the wrong place at the 
wrong time).  
When in excess, sphingolipids behave as lipotoxic lipid species. Amongst them, ceramides and 
sphingosines are considered the “usual pathogenic suspects”. The biochemical processes of 
biosynthesis and remodelling of ceramides/sphingolipids are undoubtedly complex involving at least 
three well-characterised pathways described in detail elsewhere [1, 2]. These biosynthetic pathways are 
highly compartmentalised within the cell, which leads to the formation of discrete organelle lipid pools 
accumulating specific ceramide and other sphingolipids species. Their topographic localisation within 
the cell determines their supplied/targeted structures and also affects their signalling responses to 
extracellular and/or intracellular stimuli. Thus, it is the biochemical repertoire of sphingolipid molecules 
(e.g. sphingomyelin, ceramide, C1P, sphingosine, S1P as well as other complex sphingolipids), but also 





As typically observed in insulin resistant diabetes and also in some cancers, excessive accumulation of 
sphingolipids causes toxicity. In addition to their absolute abundance and localisation, the relative 
proportions of their specific biochemical species is also pathologically relevant. This concept has 
recently been coined as the “sphingolipid rheostat” [9], which refers to the relevance of  the coordinated 
regulation and balance of specific sphingolipids (ceramides, sphingosine and S1P) for the control of 
cellular responses. This concept was originally studied in the field of cell fate and cancer, but recent 
investigation has demonstrated its validity for metabolic pathologies such as cardiovascular diseases 
[10, 11] and diabetes [12]. Therefore, this paradigm needs to be revisited to include new regulators of 
sphingolipid metabolism as well as the paracrine action of some of those sphingolipids [13].  
The dysregulation of the rheostat either by increasing or decreasing specific types of 
sphingolipid species may exacerbate the pathology, may be used as biomarker of phenotypes or stages 
within the natural history of the disease, and could be helpful to identify nosological entities. Thus, 
sphingolipid profiles could be used as diagnostic, prognostic and therapeutic responsiveness biomarkers 
of metabolic stress and disease. 
The current interest on the pathophysiological role of sphingolipids has been sparked by 
enabling technologies such as cellular and in vivo knockout models and improved lipidomic platforms. 
Technologies such as genetic engineering/editing and mass spectrometry have helped to elucidate the 
function of sphingolipid and glycerophospholipid regulated pathways, recognise their direct 
contribution to toxic cellular effects, and have identified new allostatic pathways designed to restore or 
maintain cellular homeostasis. The two most recognised sphingolipid-mediated toxic effects at cellular 
level are mitochondrial and endoplasmic reticulum stress and apoptosis [14, 15]. Another important but 
underestimated target of sphingolipid/ceramide mediated toxicity is the perturbation of 
glycerophospholipids homeostasis and their associated signalling events, the main focus of this 
review. 
Using systems biology, Koberlin [16] and Vonkova [17] have provided new evidence for the 
close bidirectional interaction between sphingolipids and glycerophospholipids. Koberlin et al. have 





a circular network of co-regulated lipids [16]. Their elegant approach has revealed a fundamental inter-
lipid regulatory network that controls membrane lipid composition. Interestingly, these membrane lipid 
perturbations predicted the inflammatory responses in patients derived cells; enabling the functional 
assignment of lipids to specific Toll-like-receptor (TLR) signalling. Moreover, Vonkova and colleagues 
have shown the existence of cooperative (and also a few deterring) interactions between 
phosphatidylinositides (acting as driver ligands), and sphingolipids (in an auxiliary role), that mediate 
the recruitment of PH containing proteins to the membranes in both yeast and higher eukaryotic models. 
Moreover,  in many cases, these cooperative events are highly specific and restricted to specific pairs 
of signalling lipids  [17]. Thus, accumulating evidence indicates that both, sphingolipid and 
glycerophospholipid metabolism is essential for cellular membrane dynamics. Both types of lipids 
mutually regulate their biosynthesis and signalling paths within eukaryotic cellular models.  
Our perception after reviewing the subject is that both, sphingolipid and glycerophospolipid 
metabolism are highly connected, integrated and driven in opposed directions, representing a harmonic 
“Ying and Yang” model of regulation contributing to  membrane lipid  homeostasis and lipid signalling 
events. Below, we provide the current experimental evidence supporting the existence of this regulatory 
crosstalk. 
3. Evidence that sphingolipid metabolism is essential for cellular membrane dynamics and 
signalling. 
Sphingomyelins and ceramides are present in the lipid rafts and caveolae domains of the plasma 
membrane. The relative concentration of sphingolipids, phospholipids and cholesterol [18-25] 
determines its biophysical properties varying from gel to liquid-ordered and to liquid-disordered 
structures [26, 27]. Other sphingolipid species, such as sphingosine or ceramide-1-phosphate, are also 
present in membranes at lower concentrations. Despite their low concentration, these lipids play 
essential roles as determinants of membrane dynamics and signalling pathways. For instance, 
sphingosine permeabilises phospholipid bilayers and increases vesicle leakage [28]; S1P modifies the 





is required for the formation of a negative membrane curvature [30] and it is not segregated into lateral 
lipid domains in phospholipid bilayers [31]. 
The use of artificial liposomes and in vitro cellular models have documented how temperature 
[32] and/or other mechanical stresses affect the interaction between ceramides and the other constituents 
of the plasma membrane [33]. There is evidence from these in vitro models that both, quantitative 
(relative percentage) and qualitative changes (length and unsaturation of fatty acid moieties) [34, 35] in 
sphingolipids (mostly ceramides and sphingomyelins) [36-43] perturb the biophysical properties of the 
plasma membrane (e.g. fluidity, lateral pressure and diffusion). These are non-subtle membrane 
perturbations and are likely to compromise metabolite transport and diffusion, receptor signalling, 
sorting and trafficking, formation of pores (e.g. in the outer membrane of the mitochondria [44]) and 
activation of apoptotic stimuli. 
 At physiological levels, SMs stabilise the interactions with sterols in bilayer membranes [45, 
46] and regulate the trans bilayer movement and distribution  of diacylglycerols (DAGs) [47] and 
galactosylceramides [48]. In contrast, ceramides -when in excess- associate with SM/PC and 
destabilise/ displace cholesterol within the membrane (reviewed in [26, 49, 50]). Ceramides facilitate 
the transbilayer lipid movement in membranes, which occurs irrespectively of whether ceramides are 
externally sourced or obtained by metabolising SM via SMases [51]. Additionally, there is evidence 
that ceramides spontaneously translocate (with limited capacity) from the outer to the inner leaflet of 
the plasma membrane [52, 53], which is relevant for signalling and trafficking. The position of 
ceramides in the inner or outer side of the membrane is important given their role promoting plasma 
membrane repair in response to injury [54] and control of exocytosis or endocytosis [55], processes that 
require the involvement of a functional plasma membrane.  
Genetically modified murine models have helped to identify the primary effects on energy homeostasis 
of sphingolipid-related gene ablation. These experiments have also revealed robust compensatory 
mechanisms aiming to maintain cellular and tissue homeostasis, some of them of therapeutic potential. 
For instance, the SMS2KO mouse exhibited a healthy phenotype characterised by impaired fatty acid 





[39]. Alterations in membrane lipid microdomains associated with CD36/FATP1 transporters and 
CAV1 [40] ultimately lead to decreased lipid storage. Conversely, overexpression of sphingomyelin 
synthases, SMS1 and SMS2, caused a pro-atherogenesis phenotype characterised by aggregation of 
lipoprotein particles [56].  Also interesting is the effect of sphingomyelin ablation on cellular signalling. 
Particularly, SMS deficiency or overexpression are expected to change membrane microdomains (lipid 
rafts, caveolae) enriched in SM, affect their biophysical properties and compromise transport, secretion, 
and signalling mechanisms such as apoptosis and cell death [57]. Furthermore, SMS1 and SMS2 
deficiency/overexpression also affect the levels of sphingosine and S1P [58, 59] that could potentially 
act as second messengers. In the light of recent investigations it has been suggested that S1P may 
contribute to the development of insulin resistance in mice [60-63]. Thus, it is tempting to speculate 
that changes in S1P in those models may contribute to their overall phenotype.  
Whereas the in vivo evidence for the crosstalk between sphingolipids and glycerophospholipids 
is still limited, the in vitro models have shown that sphingolipids and glycerophospholipids interact at 
a functional level. Moreover, this crosstalk goes beyond what could have initially been anticipated given 
the relatively marginal structural disruption observed from gain or loss of function genetic experiments. 
These in vitro studies show the direct regulation of glycerophospholipids metabolism by sphingolipids 
by interfering with major phospholipases, such as PLA2, PLC and PLD, releasing  lysophospholipids 
and fatty acids that could act as signalling metabolites.  
4. Evidence of the crosstalk between sphingolipid and glycerophospholipid metabolism. 
Beyond the linear lipid biosynthesis pathways, accumulating evidence shows that these pathways 
crosstalk and intertwine with others metabolic networks. These interactions are evolutionary preserved 
in plants, fungi, protozoa, yeast as well as in invertebrates and vertebrates (reviewed in [64]). 
One important crosstalk between sphingolipid and glycerophospholipid metabolism is the metabolic 
pathway modulating the conversion of sphingolipids to glycerophospholipids regulated by the S1P lyase 
recently reviewed by Kihara [65]. Briefly, degradation of S1P and sphinganine (dihydrosphingosine) 





phosphoethanolamine. When these fatty aldehydes are oxidized and converted into palmitoyl-CoA by 
the concerted action of several enzymes, it enters the biosynthesis pathway of glycerophospholipids. 
Recent evidence also suggests that degradation of sphingosine and sphinganine may contribute to the 
biosynthesis of etherlipids (ether analogues of phospholipids) when the activity of the fatty aldehyde 
dehydrogenase (e.g. ALDH3A2) is inactive [66]. This suggests that interlipid conversion may be a 
common allostatic response in pathologies characterised by sphingolipid alterations. Interestingly, this 
lipid interconversion may lead to lipotoxicity as the hexadecenal is able to form aldehyde-derived DNA 
adducts  [67]. The relevance of this in pathophysiological scenarios has not been investigated yet.  
In the same line of evidence, Kondo et colleague have shown that phytosphingosine can also be 
metabolised to odd-numbered fatty acids and incorporated into glycerophospholipids, both in yeast and 
mammalian cells, or alternatively undergo mitochondria oxidation [68]. However, further investigation 
will be required to fully understand the biological significance of this pathway in overall lipid 
homeostasis. 
2.1 Evidence for a cross talk between sphingolipids and phosphatidylethanolamine 
Phosphoethanolamine, the other degradation product of S1P and sphinganine, can enter the CDP-
ethanolamine pathway to generate phosphatidylethanolamine (PE) [69-71]. Moreover, PE can be 
further converted to other glycerophospholipids such as PC and PS, via PEMT and PDSS2 enzymes 
respectively. 
 Proof of this close relationship between sphingolipids and phosphatidylethanolamine is the evidence 
that genetic manipulation of sphingolipids biosynthesis impairs PE homeostasis by limiting substrate 
availability. For instance, the simultaneous ablation of Sphk1 and Sphk2 [72] (the enzymes responsible 
of the phosphorylation of sphingosine to S1P) and the S1P lyase in vivo [72, 73] decreased PE levels 
and accumulated  sphingosines, ceramides and sphingomyelins -as a result of the direct reutilization of 
the sphingosine backbone- [73] These data indicates that the biosynthesis of glycerophospholipids from 
sphingolipids intermediates is essential for the degradation of sphingolipids [74] and that perturbations 





significance for the survival of the protozoan parasite leishmania being the major route for ethanolamine 
synthesis [75]. 
Additional evidence showing that sphingolipid metabolism affects glycerophospholipid pools comes 
from studies showing that ceramides also inhibit the CDP-ethanolamine 1,2 diradyl-sn-glycerol 
ethanolamine phosphotransferase (EPT) and reduce the levels of PE [69, 76]. Moreover, several in vitro 
and in vivo models of impaired biosynthesis of ceramides have shown both quantitative [16] and 
qualitative changes in the pools of PEs [43, 77] suggesting the presence of compensatory mechanisms. 
Whether this opposed direct action of ceramides vs. S1P regarding PE metabolism is part of a regulated 
homeostatic rheostat is at the present moment unknown.  
Intriguingly, similar to PC (see section below), PE contributes to the biosynthesis of ethanolamine 
containing analogues of SM [78]. Thus, it is also conceivable that PE levels may limit the biosynthesis 
of specific sphingolipid species, in the same way that PCs do. 
2.2 Sphingolipid mediated inhibition of phosphatidylcholine biosynthesis. 
Short chain ceramides but not their structural analogues dihydroceramides [79], prevent the 
biosynthesis of PCs by inhibiting the enzyme CCT [76, 80-82]. Inhibition of CCT requires activation 
of cPLA2 and subsequent release of lysophosphatidylcholine (LPC) [83]. CTT activity and mRNA 
gene expression is also repressed by sphingosine [84]. Interestingly, the inhibitory effect of sphingosine 
on CCT is reversed in the presence of other glycerophospholipids such as PS, PI and PG [85].  
The inhibitory effect of ceramides on PC biosynthesis is tightly controlled and apparently 
independent of the source of ceramides. Thus, in vitro experiments in lung epithelia overexpressing 
ceramide synthase 5 (CerS5) and/or sphingomyelinase (SMase) have shown an additive effect 
mediating the inhibition of the biosynthesis of phosphatidylcholine. Conversely, PC biosynthesis is 
stimulated when Cers5 is downregulated by SiRNA [86]. These data suggest that the PC biosynthetic 





Similarly, SM analogues  also inhibit the translocation and activation of CTT [87, 88].  Thus, 
the impairment in PC biosynthesis resulting from increased level of ceramides may be relevant to 
disease pathogenesis and has been proposed as one of many mechanisms for how aSMase may 
contribute to steatohepatitis [89]. Conversely, glucosylceramides have been shown to  activate CTT as 
observed in in vitro models of Gaucher disease [90].  
In line with these findings, global lipidomic analysis has lent further support to the existence of 
a solid crosstalk between sphingolipids and PC. For instance, the knock-down of sptlc2 in RAW264 
macrophages increases the levels of PC [16]. Similarly, the total knock-out of sptlc123 in Huh7 
hepatocytes results in increased phospholipids with an enrichment in PC species [91]. Paradoxically, 
the sptlc2 heterozygote  [39] and the heart specific sptlc2 KO [92] mice exhibited a decrease in the  PC 
levels as well as qualitative changes in the FA of the PC fraction. These data suggest that the changes 
observed in the PC pools in these models are likely secondary homeostatic responses directed to 
preserve cellular or tissue viability.  
Moreover, sphingolipids also regulate the pool of PCs through indirect mechanisms. An 
illustrative example of this is the influence of SM levels on the hydrolysis of PC pools from VLDL, 
LDL and HDL lipoproteins by hepatic lipase (HL) (see also section 5.2). Thus, SM depletion stimulates 
the hydrolysis of PC (mainly PUFA-PC) as well as TG, indicating that SM acts as an inhibitor of HL 
[93]. Another effect relates to the activation of the ABCB4 receptor expressed in the canalicular 
membrane of hepatocytes whose function is to export PC into the bile. In this regard, Zhao and 
colleagues have shown that the cellular content of SM is critical for ABCB4 to facilitate the efflux of 
PC, opposite to the effects of other members of the ABC family such as ABCB1 [91]. 
PCs also reciprocally regulate sphingolipid metabolism. Examples of this regulation include: 
a) the activity of PCs acting as phosphocholine donors for SM biosynthesis [94-97]; b) the fact that 
choline deficient media/diets [98] or that pharmacological inhibition of choline kinase [99], both impair 
the synthesis of SM while concomitantly increasing ceramide levels. Conversely, the action of SMase 





generation of phosphatidylcholine [100]. Altogether these data  strengthen the concept of a strong co-
regulation between PC and SM biosynthetic and metabolic pathways. 
2.3 Evidence for a crosstalk between sphingolipids and phosphatidylserine. 
Serine is a common component of both PS and ceramides, suggesting that both types of lipids 
may be metabolically connected. This biochemical link has been confirmed by in vitro where labelled 
serine originated from PS was identified in ceramides [101]. Moreover,  sphingosine, S1P and lyso-
sphingomyelin increase the biosynthesis of PS and block the conversion of PS to PE by decarboxylation 
[102, 103] mediated by a PKC independent mechanism [104, 105]. In support of this regulatory loop, 
the ablation of sptlc2 gene in RAW264 macrophage caused the expected impairment in the de novo 
biosynthesis of ceramides but also decreased the levels of PS.  Similarly, the elevation of SM mass by 
different mechanisms  leads to the depletion of the PS pool from the plasma membrane [106] leading 
to mislocalisation of k-ras [33], this was prevented by inhibition of SM synthesis suggesting the 
existence of a concerted mechanism to regulate the levels of both lipids in the plasma membrane. 
In addition to SM, other sphingolipids also affect the location of PS in   the plasma membrane 
as well as some of the biochemical processes regulated by PS. Thus, the ceramides generated by 
activation of SMSase facilitate  the synthesis of  PS and also contribute to the translocation of PS to the 
outer membrane, a requirement for platelet secretion and thrombus formation [107]. Other sphingolipids 
such as sphingosines, due to their positive charge, prevent the binding of calcium to PS enriched vesicles 
[108-110] and/or negatively modulate substrate phosphorylation by PKC by directly competing with 
PS [111, 112]. This evidence indicates that ceramides facilitate PS biosynthesis and optimise cellular 
location, whereas other sphingolipids elicit a negative effect on PS homeostasis. 
It is worth noting that a recent investigation in the forebrain of CerS6KO mice [113] has shown the 
paradoxical increase in PS levels. This may be interpreted as against ceramides having a positive effect 
on the PS pool. Nevertheless, in this model there is a specific depletion of C16:0 ceramides rather than 






 In terms of our ying/yang concept, the yang of this erregulation is that phosphatidylserine 
reciprocally modulates sphingolipid metabolism. For instance, PS increases the activity and 
translocation of sphingosine kinase to membranes [114, 115]  and also activates enzymes involved in 
the degradation of complex sphingolipids [116, 117] . Whether PS interferes with the activity of SMase 
is less clear as some studies have shown that PS inhibits PKC mediated activation of neutral SMase 
[118], whereas others indicate that PS stimulates neutral  [119] and alkaline [120] SMSase activities. 
PS also reverses some of the negative effects of sphingolipids on enzymatic activities. PS (as 
well as PI but not PC) reverses sphingosine mediated inhibition of transmembrane protein 
tyrosylprotein sulfotransferase (TPST), the enzyme that catalyzes the sulfation of tyrosines. Despite the 
molecular mechanism not being well characterised,  the authors concluded that the positive charges of 
sphingosine and a long alkyl chain are fundamental for impairing the affinity of the protein-substrate 
and that PS is able to reverse that inhibition in a competitive manner [121]. 
 Similarly, PS also reduces the inhibitory effect of sphingosine on the autophosphorylation of 
the insulin receptor tyrosine kinase [122]. In this regard, it has been suggested that the high affinity for 
PS may protect the receptor from interacting with the amine group of sphingosine. Globally, these 
investigations suggest that acidic phospholipids, such as PS, may prevent the interaction of sphingosine 
with the targeted proteins. Given that sphingosine inhibits other kinases such as SRC kinase [123], it is 
conceivable that this competitive interaction between sphingosine and PS may be common  in other 
similar kinases. Further research will be needed to evaluate the biological significance of this 
competitive interaction. 
2. 4 Bidirectional Crosstalk between Sphingolipid metabolism and Platelet Activating Factor.  
 Platelet Activating Factor (PAF) is an ether-glycerosphospholipid important for immune cell 
activation. The first insight for an interaction between PAF and sphingolipid biosynthetic pathways 
came from the discovery of a CoA independent transacetylase that mediates the transfer of an acetyl 
group from PAF in the synthesis of N acetylsphingosine [124-126]. More recently, we have learned that 





in immune cells. Conversely, PAF increases SMase activity and facilitates the generation of ceramide 
microdomains, which are important for inflammation, apoptosis, activation of eNOS in EC cells [129], 
development of pulmonary oedema [130], and the activation of the enzyme scramblase that facilitates 
the exposure of PS in the outer membrane [131]. 
3. Sphingolipids modulation of phospholipid biosynthesis via SREBP activation.  
How sphingolipids regulate the biosynthesis of phospholipids at a molecular level is a key question. 
SREBPS are important mediators of the biosynthesis of fatty acids, cholesterol and TGs. SREBPS also 
regulates the levels of phosphatidylcholines by regulating the expression of pcyt1a (the gene that 
encodes CTT) at transcriptional and posttranscriptional mechanisms level [132, 133]. SREBPS may 
also indirectly increase pcyt1a expression and activity secondarily to the concomitant biosynthesis of 
fatty acids. Genome-wide analysis of SREBP1 binding in mouse liver has shown the presence of 
putative SRE motifs in the phosphatidylinositol synthase gene [134], suggesting that the regulation by 
srebp1 might not be restricted to PC biosynthesis. This concept is further reinforced by novel research 
in flies [135] and metazoans [136]. 
Sphingolipids control SREBP1 cleavage and activation by different mechanisms: a) the breakdown of 
sphingomyelins to ceramides in the plasma membrane displaces cholesterol to intracellular 
compartments where cholesterol represses the cleavage and activation of srebp1 and 2 [137]. Additional 
evidence indicates that high levels of ceramides resulting from SM hydrolysis inhibit SRE mediated 
gene transcription independently of changes in intracellular cholesterol trafficking through a 
mechanism not yet defined [138] and  b) S1P stimulates SREBP1 cleavage and nuclear translocation 
via a S1P receptor [139].  
Sphingolipids also regulate SREBP1 expression. For instance, ceramides have been reported to 
increase the levels of the precursor SREBP and decrease the levels of mature SREBP [140]. Moreover, 
accumulation of SM (either from external origin or as a result of the inhibition of SMase) represses  
srebp1 expression via a caveolin and Ras-ERK-MAPK-CREB signalling pathway in adipocytes [141]. 





of the LXR-SREBP1 pathway [142]. The potential pathophysiological relevance of these findings is 
highlighted by a recent study showing that increased levels of SMs are associated with decreased levels 
of srebp1 mRNA in the adipose tissue of obese women [141].  
Altogether, this indicates that sphingolipids may regulate lipid homeostasis (including PC 
biosynthesis), by controlling both the expression and activation of SREBP1. This may be of particular 
relevance in tissues such as liver and adipose tissue where SREBP1 is an important regulator of lipid 
synthesis, and where its dysregulation contributes to the development of NAFLD and obesity associated 
adipose tissue dysfunction. 
4. Sphingolipids interfere with phospholipid mediated signalling.  
4.1 Sphingolipids modulate the biosynthesis and activity of phophatidylinositols.  
Compared to the robust effect of sphingolipids on other phospholipids, the evidence that 
sphingolipids may interfere with the de novo biosynthesis of phosphatidylinositol phospholipids in high 
eukaryotic cells is still preliminary. However, it is known that the small subunit of the serine 
palmitoyltransferase (ssSPT) [143] is also a lysophosphatidylinositol acyltransferase 1-interacting 
protein [144]. Thus, this protein could be a pivotal signal co-regulating both the synthesis of ceramides 
and the biosynthesis and remodelling of PI species. Of relevance, we have recently observed that in 
adipocytes engineered with a knock down of the DEGS1 enzyme, the enzyme controlling the final step 
of the de novo biosynthesis of ceramides by promoting the desaturation of dihydroceramides to 
ceramides [79], results in decreased levels of glycerophospholipids, specially etherlipids and 
phosphatidylinositols. Whether the downregulation of these lipids is the result of the decreased 
ceramide pool, increased dihydroceramides, or alternatively occurs secondarily to homeostatic changes, 
is currently under investigation (Rodriguez-Cuenca, unpublished).  
4.1.1 Sphingolipids modulate the synthesis and signalling mediated by Phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2). 
In terms of its concentration, phosphatidylinositol-4,5-bisphosphate is a relatively minor 





proteins. Sphingosine - at low doses - activates the enzyme phosphatidylinositol-4 kinase that converts 
PI into PI4P. However, this reaction is repressed when sphingosine is present at high concentrations as 
a result of the biosynthesis of sphingosine phosphate [145, 146]. Additionally, gangliosides also activate 
PIP5K and increase PI(4,5)P2, which contributes to the inflammatory response via NKFB activity [147]. 
Thus, these data strongly support that sphingolipids both regulate the biosynthesis of PI derivatives and 
interfere with their signalling events.  
Quantitative changes in the sphingolipid pools of the plasma membrane are 
pathophysiologically relevant as they perturb the microenvironment and compartmentalization of 
PI(4,5)P2, and compromise the recruitment of specific signalling proteins to the membrane. Some 
illustrative examples of this link between sphingolipids and impaired signalling are: a) increased levels 
of ceramides resulting from the ablation of Ceramide Kinase (CERK) directly impair PI(4,5)P2 
processing by PLC and prevent the recruitment of photoreceptors in drosophila cells [148]; b) depletion 
of SM in otherwise typically rich domains, disperse PI(4,5)P2 and inhibit the recruitment of GTPases 
leading to abnormal cytokinesis in Hela cells [149].  
Moreover, sphingolipids directly compete but also occasionally synergise with the effect 
exerted by PI(4,5)P2 on different enzymes and proteins. For instance, whereas PI(4,5)P2 facilitates the 
phosphorylation of ERM proteins in the plasma membrane (which plays a crucial role in the 
organization of membrane domains through interaction with transmembrane proteins and the 
cytoskeleton), ceramides exert the opposite effect and repress ERM phosphorylation by activating 
phosphatases [150]. Another example of the opposing effects between sphingolipids and PI(4,5)P2, 
comes from studies on phospholipases. Here, ceramides inhibit PLD activity by competing for its 
catalytic core with PIP2 (activator) [151]. Similarly, SMs also compete -against PIP2- and repress PLCδ1 
[152]. However, in its phosphorylated form, ceramide-1-phosphate, does not compete but actually 
synergises with PIP2 activation of PLA2G6 by modulating their interaction with PC in the membrane, 
and/or by increasing the catalytic efficiency respectively [153]. In this regard, an interesting finding in 
yeasts, which are theoretically transferable to higher eukaryotic cells, is that PI(4,5)P2 (as well as other 





a variety of sphingolipids such as dihydroceramides, dihydrosphingosines in targeting PH domains to 
membranes [17].  
4.1.2 Sphingolipids modulate the signalling mediated by Phosphatidylinositol 3,4,5-trisphosphate 
(PI(3,4,5)P3). 
Phosphatidylinositol 3,4,5-trisphosphate is the product of phosphorylation of 
phosphatidylinositol (4,5)-bisphosphate by PI3K and localises to the plasma membrane. One of the key 
signalling events regulated by PI3K is the activation of AKT. The activation of PI3K converts PI(4,5)P2 
into PI(3,4,5)P3 and facilitates the binding of PI(3,4,5)P3 to the pleckstrin homology domain of protein 
kinase B/AKT. This induces both a conformational change and translocation as well as further 
activation by Ser473 phosphorylation via PDK1. Like AKT, PDK1 also possesses a 
PI(3,4,5)P3/PI(3,4)P2 binding Pleckstrin homology domain (PH) domain, necessary for PDK1-mediated 
phosphorylation of Thr308 and full AKT activation [154-159]. 
 From the pathophysiological point of view, one of the most studied lipotoxic effects of 
ceramides in the context of insulin resistance, is the spatio-temporal dependent impairment of 
PI3K/AKT [160, 161]. The mechanisms through which ceramides interfere with PI3K signalling 
include the PPA2 mediated dephosphorylation of AKT Ser 473 [160, 162-165] and the inhibition of the 
recruitment of CAV1 to PI(3)K-associated receptor complexes within lipid raft microdomains [166]. 
Of note, ceramides disable the binding of PI(3,4,5)P3 to the plecktrin homology domain of PKB/AKT, 
an effect mediated by activated PKCz and the subsequent phosphorylation of PKB/AKT [160, 162-164, 
167]. Through this mechanism, ceramides impair the activation and translocation of insulin induced 
AKT kinase [168] and contribute to insulin resistance. Interestingly, the long chain ceramides directly 
interact with the catalytic domain of the PI3KC2b subunit, which disturbs its compartmentalization and 
suppresses its activation [169]. Additionally, the negative effect of ceramides on PI(3,4,5)P3 related 
signalling also involves other domains that impair the translocation of certain PI(3,4,5)P3-binding 
proteins such as GRP1 (general receptor for phosphoinositides-1), even in the presence of PI(3,4)P2 or 





S1P activates the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway via S1P 
receptors (coupled with Gi) and modulates a variety of cellular processes including cell proliferation, 
migration and stress response [171-173]. This contrasts with the observation that S1P reduces the ability 
of insulin to induce AKT phosphorylation via S1P2 receptor in muscle cells [63, 174] and highlights 
the differences amongst the three classes of PI3K members (class I that produces PI(3,4,5)P3, and class 
II and III that produces PI(3P) and the cell specific peculiarities of similar signalling pathways. 
In summary, the above data suggest that sphingolipids interfere with PI derivatives by affecting 
their biosynthesis and metabolism, and by competing with their signalling processes. This supports the 
concept that lipotoxic effects mediated by sphingolipids involve physicochemical changes in 
membranes as well as impairments in both signalling and metabolic reactions and contributes to 
common disorders such as insulin resistance and diabetes. The impact of sphingolipids on other 
phosphatidylinositol related signalling events in the context of disease has not yet been elucidated. 
4.2 Phosphoinositides regulate sphingolipid metabolism. 
There are also reciprocal effects between phosphatidylinositol metabolites and sphingolipid 
metabolism. This is particularly relevant in yeast, where PI provides phosphoinositol for the generation 
of inositolphosphorylceramides [175]. In addition to this direct metabolic link found in yeast, there is 
also a regulatory mechanism mediated by Pkh1, Torc2 and Ypk1 [176-178] that coordinates the 
biosynthesis of PI/phosphoinositides and sphingolipids. This co-regulation is essential to adjust the 
membrane lipid composition and maintain its integrity particularly in response to environmental stress.  
In higher eukaryotic cells for instance, PI(3,5)P2 is a potent and specific inhibitor of acid 
sphingomyelinase (aSMase) and therefore blocks the generation of pro-apoptotic ceramides [179-181]. 
However, phosphatidylinositol ether lipid analogues exert the opposite effect inducing apoptosis via 
activation of SMase and concomitantly increase in ceramide levels [182]. Another mechanism 
mediating this crosstalk is illustrated by PI(4,5)P2, which has been shown to interact with the PH domain 
of ceramide kinase (CERK) and regulate its location to the Golgi and plasma membrane targeting. The 





Additionally, PI(4,5)P2 and PI4P have been shown to modulate the activity of Sphingosine kinases 1 
and 2 [184, 185]. 
Another example of multifaceted crosstalk between sphingolipids and PI derivatives is that 
PI4P - generated by a PI4 kinase IIIbeta- regulates the flow of ceramides between the ER and Golgi, 
and favours the synthesis of sphingomyelin by binding to the N-terminal pleckstrin  homology domain 
of a ceramide transport protein (CERT) [186, 187]. This process is regulated by cholesterol as it affects 
the activity of PI4KIIa- by altering its membrane microenvironment- and by facilitating the recruitment 
of CERT to the Golgi where it promotes SM biosynthesis [188]. Additionally, the availability of PI4P 
synthesised by PI4 kinase IIIbeta and PI4KIIa also contributes to the delivery of beta-
glucocerebrosidase (an enzyme relevant for the degradation of glucosylceramide) to the lysosome 
[189].  
Overall, these examples show that both sphingolipids and PI derivatives, exert bidirectional 
regulatory roles in signalling. Intriguingly, the existence of cross-regulation between these lipid families 
suggests the existence of a tight homeostatic mechanism designed to regulate the relative abundance of 
each other lipid species. This raises the possibility that pathologies characterised by defects in 
sphingolipid metabolism may benefit from strategies targeting phosphatidylinositol metabolites and 
viceversa. 
5. Sphingolipids modulate phospholipid composition and signalling via regulating phospholipase 
activity. 
In addition to the direct effect of sphingolipids on the biosynthesis of glycerophospholipids and their 
derivatives, there is also evidence that modulation of signalling pathways by sphingolipid is directly 
dependent on the metabolisation of phospholipids by major phospholipases as outlined below. 
5.1 Sphingolipids regulate Phospholipase C (PLC) activity.  
Phospholipase C includes a group of lipases that catalyse the hydrolysis of the linkage between 
glycerol and phosphate in glycerophospholipids, releasing DAG and choline-P from PC, and inositol 





PLCδ1 and PLC through a mechanism dependent on the chain length and unsaturation index of the 
fatty acid moieties [190-193]. Conversely, in liposome based studies, sphingosine has been described 
to activate PI-PLC by direct physical interaction with PLC- in a calcium dependent manner [194, 195]. 
Alternatively, sphingosine as well as S1P were reported to activate PLC, enhancing PI turnover and 
calcium mobilization via G protein interaction [196-198], which supports an extracellular action of S1P. 
The discovery of S1P receptors (for a detailed review see [199, 200]) as mediators of such effects was 
described later on [201]. In this regard, the coupling of several S1P receptors (S1P1-4) to particular G 
proteins (Gi and Gq) has been demonstrated to activate PLC in a variety of cellular models [202, 203]. 
In the same line of evidence, C1P also activates PI-PLC and increase the levels of S1P [204], 
unfortunately the precise molecular mechanism is currently unknown. 
An example of sphingolipids modifying PLC activity occurs in response to HDL associated 
sphingolipids. HDL in addition to glycerophospholipids, steroids, triacylglycerides and cholesteryl 
esters carries several sphingolipids including sphingomyelin, ceramides and lysosphingolipids [205] 
and their dysregulation has been associated to vascular dysfunction and Metabolic Syndrome [206]. 
Among them, S1P is the best characterised in relation to vascular biology [207]. Other biologically 
active lysophospholipids in HDL are lysosulfatide and sphingosylphosphorylcholine. Interestingly, 
these two lysophingolipids trigger specifically PI-PLC activation and stimulate cell proliferation in 
contrast with the Apo AI activation of PC-PLC associated with induced cholesterol efflux [208]. Here 
authors suggested that these lysophingolipids could account for some anti-inflammatory effects 
mediated by HDL. These data support the concept that qualitative changes in the HDL sphingolipidome 
modify the physico-chemical properties of lipoproteins, impact signalling cascades mediated by PLC 
(as well as other lipases and phospholipases) and ameliorate or exacerbate the atherogenic risk. In this 
regard, despite the evidence in rodent models that overexpression /repression of SMS increase/decrease 
the atherogenic potential respectively [56, 58] the contribution of secondary changes in the 
glycerophospholipids and their metabolites was not evaluated. 
Another revealing example of how sphingolipid metabolism interacts with 





alkaline SMase also directly hydrolyses PAF working as putative phospholipase C, removing the 
phosphocholine head group and generating 1-O-alkyl-2-acetyl-sn-glycerol. Interestingly, the hydrolysis 
of PAF and SM can be counterregulated by the presence of SM and PAF respectively [209]. If this 
apparent promiscuity is part of a  regulatory mechanism that controls the levels of specific 
glycerophospholipids by different members of the sphingolipid family and enzymatic repertoire will 
need to be addressed in the future. 
5.2 Sphingolipids regulate Phospholipase D (PLD) activity.  
Phospholipase D catalyses the cleavage of the phosphodiester bond of structural phospholipids 
and releases phosphatidic acid (PA), a well-established second messenger. Sphingosine and 
sphingosine-1-phosphate, both activate PLD and directly compete with the inhibitory effect exerted by 
PE and PC [210-215], through both PKC dependent and independent mechanisms [216]. One of the 
mechanisms described for S1P as an activator of PLD is via activation of the SP1 receptor, as suggested 
by its role in control of IL8 secretion in human bronchial epithelial cells [217]. 
Sphingolipids also exert inhibitory effects on PLD. Ceramides for example inhibit 
phospholipase D, through a change in membrane biophysical properties which impair PKC 
translocation to the membrane, a required step for PLD activation [218-223]. Moreover, ceramides also 
repress the transcription of PLD mRNA in several cellular models [224-226]. This inhibitory effect of 
ceramides on PLD activity/expression is pathophysiologically relevant as indicated by its effects 
promoting: a) insulin resistance in hepatocytes [227], b) senescence [228] and c) apoptosis in granulosa 
cells [229]. However, the inhibitory effect of ceramides on PLD has been contested by some studies 
showing that it is the conversion from SM to ceramide in lipid rafts which activates PLD [230]. 
Therefore, it cannot be excluded that the activation of PLD is driven by the secondary conversion of 
ceramides to other bioactive sphingolipids. 
Conversely, the PA released upon PLD activation regulates sphingolipid homeostasis. For 
instance, PA inhibits C1P stimulated macrophage migration [231], facilitates the translocation of 





phosphatase 1 by ceramides [233]. Recently, Demirkan et al. identified a strong association between a 
SNP in PLD2 (rs12051548) and the ratio of sphingomyelins SM(d18:1/23∶0) / SM(d18:1/16∶1) in a 
GWAS study [234].  Nevertheless, the possible molecular mechanism responsible for such interaction 
is currently unknown. Globally considered, these data strongly support the existence of a bidirectional 
cross talk between sphingolipids and derivatives of glycerophospholipids that determine the 
biochemical repertoire and concentrations of second messengers.  
5.3 Sphingolipids regulate phospholipase A2 activity.  
 PLA2 enzymes play an important role in lipid mediated inflammatory processes, signalling and 
phospholipid remodelling. Specifically, PLA2 phospholipases hydrolyse the bond at the second carbon 
group of glycerol, releasing the fatty acid moiety located in the sn2 position (e.g. arachidonic acid) and 
the corresponding lysophospholipid [235]. Several families of enzymes exist according to their 
dependence on calcium, location, substrate preference, specific roles in signalling, immune response 
and phospholipid remodelling.  
5.3.1 Sphingolipids regulate cytosolic and calcium-independent phospholipase A2 
Ceramide, ceramide-1-phosphate, sphingosines and other complex sphingolipids regulate the 
activity of cytosolic PLA2 (cPLA2) and the release of arachidonic acid (AA) in many cell types. For 
instance, C1P, sphingosine and lactosylceramide directly bind to the calcium binding (C2) domain of 
cPLA2a (PLA2G4A), facilitating its translocation from cytosol to Golgi (into PC rich areas) and 
activating the release of AA from substrate phospholipids [236-244]. This phenomenon is essential for 
biological processes such mast cell degranulation [245], stimulation of cell adhesion pathways between 
monocytes and endothelial cells [246], and vasodilation [247]. Most importantly, they contribute to the 
activation of prostaglandin biosynthesis in response to calcium and inflammatory agonists such as 
TNF, ILβ1 [248, 249]. Another much less studied cPLA2, the plasmalogen selective PLA2, seems to 
be activated by ceramides in the brain [260, 261]. Interestingly, recent investigations in the liver  of 
alcohol-dependent patients have proposed the activation of cPLA2 as a potential mechanism linking the  





increase in hepatic  LPC [250]. Interestingly, increased levels of both LPC [251, 252]  and ceramides 
[253]  have been also shown in NAFLD patients. Whether this increase in LPC is secondary to a 
ceramide mediated activation of PLA2 or part of secondary homeostatic response/or lipotoxic insult 
will required further research. 
In addition to the direct activation of cPLA2 by ceramides and derivatives, cPLA2 is also 
activated through indirect mechanisms via PKC activation [254, 255]. Moreover, cPLA2 is activated 
by C1P via JNK mediated activation/phosphorylation of Ser505 [256]. This latter mechanism has been 
considered as a cellular strategy for recycling structural phospholipids into energy generating substrates 
in CHO cells [257]. S1P also activates PLA2G6, releasing AA and LPC, which subsequently activate 
TRP5 cationic channels in HEK293 cells [258]. Conversely, other members of the sphingolipid family 
exert deterring effects on phospholipase A2 activity. For example, SM decreases the activity of cPLA2 
by disturbing its binding to glycerophospholipids, which impairs the release of AA [259, 260].  
Gangliosides are another example of inhibitors of PLA2, doing so by altering the biophysical properties 
of the membrane [261, 262]. 
Despite the fact that most of the research focused in PLA2 and ceramides has aimed to 
investigate the signalling/inflammatory events mediated by the release of fatty acids (e.g arachidonic 
acid) and lysophospholipids, it is conceivable that others aspects of PLA2 biology such as their role in 
the remodelling of phospholipids in partnership with LPLATs (lands’ cycle) will be also affected. This 
is an area which our lab is currently exploring in relation to obesity and associated comorbidities. 
5.3.2 Sphingolipids also regulate Secretory PLA2 
  Similarly to their effect on cPLA2, ceramides modify the fatty acid specificity exhibited by 
different secretory phospholipases by inducing structural defects in membrane bilayers [263, 264]. 
Additionally, ceramides mediate the TNF induced upregulation of sPLA2 (and cox2) in mesangial 
cells through NFκB activation and increase production of PGE2, strongly suggesting that this pathway 





 What could be considered the “yang” effect on this occasion would be SM mediated inhibition of the 
activity of secretory phospholipase A2. This has been shown for sPLA2-V and results in the reduction 
of the release of AA [241, 266]. SM may also modulate the binding of PLA2 to membranes, a process 
that is highly dependent on membrane cholesterol levels [267-269]. 
The opposed effect of ceramides and sphingomyelins on the activity of sPLA2 is of biological 
relevance as it affects the clearance and metabolisation of lipoproteins. When HDL and LDL are 
enriched with exogenous long chain ceramides and/or ceramides obtained from the degradation of the 
SM pool, this stimulates the activity of sPLA2V [270-272], which facilitates the release of fatty acids. 
This effect is important as it forms cholesteryl esters in macrophages [273] and promotes aggregation 
and fusion of LDL [274]. As before, SMs exerts the opposite regulatory effect by inhibiting several 
secretory PLA2s even in the presence of oxidised phospholipids, which are well known activators of 
PLA2s [270-272].  
Globally considered, these data indicate that the balance between the ceramide and SM pools 
accumulated within lipoproteins are important determinants of the release of pro-inflammatory lipids 
as well as regulators of oxLDL-induced cholesterol esterification and therefore should be considered 
modulators of the atherogenic properties of lipoproteins. 
5.3.3 Phospholipase A2 reciprocally modulates sphingolipid metabolism. 
There is evidence that certain PLA2s exert a regulatory role on sphingolipid metabolism. For 
instance a) The activation of iPLA2b (PLA2G6) during ER stress seems to activate neutral 
sphingomyelinase and promotes the generation of ceramides, causing mitochondrial dysfunction and 
activating of mitochondrial apoptotic pathways [275, 276], b) another example is pancreatic 
phospholipase A2 (sPLA2IB) which stimulates the expression of neutral sphingomyelinase and acid 
ceramidase via sPLA2 receptor [277], In this regard, these phospholipases regulate the production of 
lipid mediators by regulating the expression of key enzymes in phospholipid and sphingolipid 
metabolism through activation of their membrane receptors. All together, these studies support the 






Here we have brought together the biochemistry of sphingolipids and glycerophospholipids and 
identified current evidence supporting the existence of a bidirectional crosstalk between them. Its 
importance stems from the fact that their dysregulation can influence the progression of metabolic 
diseases. Despite the literature supporting the association between dysregulated levels of sphingolipids 
and profound changes in glycerophospholipid species at multiple levels, there is little knowledge about 
how these perturbations occur and how they may contribute to the metabolic lipotoxic burden exerted 
by sphingolipids at a cellular, tissue or organismal level, and more importantly how these changes 
specifically contribute to disease models.  
Future studies 
The development of new and more precise high-throughput analytical tools in the field of lipid 
biology and biochemistry, the availability of sophisticated bioinformatics integrative tools, in 
combination with other disciplines such as biophysics, will expand our understanding of the 
consequences of small qualitative pathophysiological changes in the lipid composition of specific 
organelles (plasma membrane, ER, mitochondria). These “new technological windows” should provide 
a more detailed picture of the existence and relevance of the bidirectional crosstalk between 
sphingolipids and glycerophospholipids, and also unravel both the impact of qualitative changes in 
particular subsets of lipids, as well as their spatio-temporal compartimentalization.  
The development of appropriate bioinformatics tools for data analysis is also essential to integrate 
their heterogeneity into workable testable models. The recent identification of several sphingolipid 
binding motifs in mammalian membrane proteins using a tailored motif probability algorithm 
(MOPRO) developed by Bjorkolm and colleagues [278] will facilitate the identification of new targets 
of sphingolipid action. Interestingly, among the 672 novel candidates identified, there are receptors for 
IP3 and LPA involved in lipid related signalling as well as for plc, scap (a regulator of srebp1), and 
mboat1 and mboat2, relevant for the remodelling of glycerophospholipids. Moreover, as new in silico 





candidate ceramide binding protein fragments among them asah1 (acid ceramidase) and mboat7 
(lysophosphatidylinositol acyltransferase) and ptgds (prostaglandin d2 synthase) [279], we envisage an 
active phase of experimental validation to understand the complex crosstalk between sphingolipids and 
glycerophospholipids biology at multiple levels. 
We believe that the use of genetically modified models to selectively increase or decrease pools of 
specific subsets of sphingolipids in a particular time/spatial frame (conditional tools) and in a precise 
organ (tissue specific) will help to dissect the relevance of sphingolipid related lipotoxicity on global 
lipid homeostasis and metabolism. These experimental models will assist in the understanding of the 
abnormal lipid profiles observed in multiple metabolic diseases such as obesity and insulin resistance, 
where both sphingolipids and glycerophospholipids are disturbed, and where, currently, it is challenging 
to specifically define a causative role for the changes in lipotoxic species (e.g. increase ceramides in 
insulin resistance models). 
 Globally considered, we are optimistic that with the power of new enabling technologies 
elucidating the regulatory networks controlling sphingolipid and glycerophospholipids homeostasis, 
and how these lipid families crosstalk, specific targets will become feasible to exploit for therapeutic 
purposes. 
 
NB. During the review of this manuscript Matsuzaki et colleagues  showed that cardiolipin bind to 
Ceramide kinase and regulate its activity and C1P levels in vitro [280], the pathophysiological 
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Figure 1. Structure of the major sphingolipids [A] and glycerophospholipids [ B]. 
Figure 2. Schematic representation of some of the mechanisms described for sphingolipid 
interaction with glycerophospholipid metabolism. [A] Modulation of plasma membrane 
dynamics. [B] Phosphatidylinositides biosynthesis and modulation of enzyme/receptor actions by 
sphingolipids. [C] Interaction with PLC, PLA2 and PLD activity. C reads for ceramides, SM 
reads for sphingomyelin, and S reads for sphingosine and S1P reads for sphingosine-1-phosphate  
Figure 3.  SREBP transcriptional and post-translational regulation: SREBP1 activity/inhibition 
is regulated depending on the environmental demands of the cells. SREBP regulates synthesis of 
the of the major long chain fatty acids that can be incorporated into triglycerides and 
phospholipids. Under conditions of high sterol and PUFA levels SREBP1 remains endoplasmic 
reticulum membrane as part of a tripartite complex with SCAP Insig1 protein preventing its 
maturation in the Golgi and its activation. 
Figure 4.  Summary of references reporting direct effects of sphingolipids on glycerophospholipid 
levels and vice versa: positive effect (green) and negative effect (red). 
Figure 5. Diagram representing the potential mechanism by which dysregulation of the 
sphingolipids/glycerophospholipid crosstalk leads to modification of cell membrane property, 
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